Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-8448b6f56d-qsmjn Total loading time: 0 Render date: 2024-04-16T20:33:43.680Z Has data issue: false hasContentIssue false

Chapter 18 - Psychotropic Drug Treatment in Later Life

from Part 3 - Specific Therapeutic Areas

Published online by Cambridge University Press:  29 May 2020

By
Simon J. C. Davies
Edited by
Peter M. Haddad  and
David J. Nutt
Peter M. Haddad
Affiliation:
Hamad Medical Corporation, Qatar
David J. Nutt
Affiliation:
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Imperial College London
Get access

Summary

In this chapter, important issues which may be encountered when prescribing medications to older adults will be discussed. It must be remembered that medication is only one of several valuable approaches in treating psychiatric disorders in the elderly and it is often necessary to integrate expertise in drug prescribing with psychotherapy and social interventions, although discussion of these is beyond the scope of this review. The first part of the chapter reviews population demographics in relation to older age psychiatry and the fact that the evidence base for using many psychiatric medications in older people is more meagre than in younger adults. This is followed by a review of the pharmacodynamics and pharmacokinetic changes seen in older adults, which can impact on prescribing.

Type
Chapter
Information
Seminars in Clinical Psychopharmacology , pp. 543 - 576
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Adams, KH, Pinborg, LH, Svarer, C, et al. (2004). A database of [(18)F]-altanserin binding to 5-HT(2A) receptors in normal volunteers: normative data and relationship to physiological and demographic variables. Neuroimage, 21, 1105–1113.CrossRefGoogle Scholar
Alaka, KJ, Noble, W, Montejo, A, et al. (2014). Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial. Int J Geriatr Psychiatry, 29, 978–986.Google Scholar
Baldwin, DS, Anderson, IM, Nutt, DJ, et al. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. J Psychopharmacol, 28, 403–439.CrossRefGoogle ScholarPubMed
Barak, Y, Wittenberg, N, Naor, S, Kutzuk, D, Weizman, A (1999). Clozapine in elderly psychiatric patients: tolerability, safety, and efficacy. Compr Psychiatry, 40, 320–325.Google Scholar
Berry, SD, Lee, Y, Cai, S, Dore, DD (2013). Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. JAMA Intern Med, 173, 754–761.Google Scholar
Bertz, RJ, Kroboth, PD, Kroboth, FJ, et al. (1997). Alprazolam in young and elderly men: sensitivity and tolerance to psychomotor, sedative and memory effects. J Pharmacol Exp Ther, 281, 1317–1329.Google Scholar
Bigos, KL, Bies, RR, Pollock, BG (2013). Pharmacokinetics and pharmacodynamics in late life. In Lavretsky, H, Sajatovic, M, Reynolds, C, eds., Late-Life Mood Disorders. New York: Oxford University Press, pp. 655–674.Google Scholar
Bishara, D, Taylor, D (2014). Adverse effects of clozapine in older patients: epidemiology, prevention and management. Drugs Aging, 31, 11–20.Google Scholar
Blier, P, Ward, HE, Tremblay, P, et al. (2010). Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study. Am J Psychiatry, 167, 281–288.CrossRefGoogle ScholarPubMed
Boustani, M, Campbell, N, Munger, S, Maidment, I, Fox, C (2008). Impact of anticholinergics on the aging brain: a review and practical application. Aging Health, 4, 311–320.Google Scholar
Bowden, CL, Brugger, AM, Swann, AC, et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania. The Depakote Mania Study Group. JAMA, 271(12), 918–924.Google Scholar
Bowie, MW, Slattum, PW (2007). Pharmacodynamics in older adults: a review. Am J Geriatr Pharmacother, 5, 263–303.CrossRefGoogle ScholarPubMed
Calati, R, Salvina Signorelli, M, Balestri, M, et al. (2013). Antidepressants in elderly: metaregression of double-blind, randomized clinical trials. J Affect Disord, 147, 1–8.CrossRefGoogle ScholarPubMed
Carew, AM, Comiskey, C (2017). Treatment for opioid use and outcomes in older adults: a systematic literature review. Drug Alcohol Depend, 182, 48–57.CrossRefGoogle ScholarPubMed
Carone, M, Asgharian, M, Jewell, NP (2014). Estimating the lifetime risk of dementia in the Canadian elderly population using cross-sectional cohort survival data. J Am Stat Assoc, 109, 24–35.Google Scholar
Chen, P, Dols, A, Rej, S, Sajatovic, M (2017). Update on the epidemiology, diagnosis, and treatment of mania in older-age bipolar disorder. Curr Psychiatry Rep, 19, 46. https://doi.org/10.1007/s11920-017–0804-8.Google Scholar
Chew, ML, Mulsant, BH, Pollock, BG, et al. (2008). Anticholinergic activity of 107 medications commonly used by older adults. J Am Geriatr Soc, 56, 1333–1341.Google Scholar
Chokhavatia, S, John, ES, Bridgeman, MB, Dixit, D (2016). Constipation in elderly patients with noncancer pain: focus on opioid-induced constipation. Drugs Aging, 33, 557–574.Google Scholar
Chung, JK, Nakajima, S, Shinagawa, S, et al.; Alzheimer’s Disease Neuroimaging Initiative (2016). Benzodiazepine use attenuates cortical β-amyloid and is not associated with progressive cognitive decline in nondemented elderly adults: a pilot study using F18-florbetapir positron emission tomography. Am J Geriatr Psychiatry, 24, 1028–1039.Google Scholar
Close, H, Reilly, J, Mason, JM, et al. (2014). Renal failure in lithium-treated bipolar disorder: a retrospective cohort study. PLoS One, 9(3), e90169. doi:10.1371/journal.pone.0090169. eCollection 2014.CrossRefGoogle ScholarPubMed
Coupland, C, Dhiman, P, Morriss, R, et al. (2011). Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ, 343, d4551.CrossRefGoogle ScholarPubMed
Crowe, SF, Stranks, EK (2018). The residual medium and long-term cognitive effects of benzodiazepine use: an updated meta-analysis. Arch Clin Neuropsychol, 33, 901–911. doi:10.1093/arclin/acx120.Google Scholar
Cumming, RG, Le Couteur, DG (2003). Benzodiazepines and risk of hip fractures in older people: a review of the evidence. CNS Drugs, 17, 825–837.Google Scholar
Davies, SJC, Eayrs, S, Pratt, P, Lennard, MS (2004). Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol, 57, 464–472.CrossRefGoogle ScholarPubMed
Davies, SJ, Burhan, AM, Kim, D, et al. (2018a). Sequential drug treatment algorithm for agitation and aggression in Alzheimer’s and mixed dementia. J Psychopharmacol, 32(5), 509–523.Google Scholar
Davies, SJC, Jacob, B, Rudoler, D, et al. (2018b). Benzodiazepine prescription in Ontario residents aged 65 and over: a population-based study from 1998 to 2013. Ther Adv Psychopharmacol, 8, 99–114.CrossRefGoogle ScholarPubMed
Department of Health Statistics and Informatics of the World Health Organization (2015). Disease burden and mortality estimates. Global Health Estimates 2015: DALYs by age, sex and cause. Available at: www.who.int/healthinfo/global_burden_disease/estimates/en/index2.html (last accessed 14.8.18).Google Scholar
Depp, CA, Jeste, DV (2004). Bipolar disorder in older adults: a critical review. Bipolar Disord, 6, 343–367.Google Scholar
Dold, M, Aigner, M, Lanzenberger, R, Kasper, S (2015). Antipsychotic augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: an update meta-analysis of double-blind, randomized, placebo-controlled trials. Int J Neuropsychopharmacol, 18(9), pyv047.Google Scholar
Doukas, N (2011). Older adults in methadone maintenance treatment: a literature review. J Soc Work Pract Addict, 11, 230–244.CrossRefGoogle Scholar
Esiri, MM, Morris, JH (1997). Practical approach to pathological diagnosis. In Esiri, MM, Morris, JH, eds., The Neuropathology of Dementia. Cambridge: Cambridge University Press, pp. 36–69.Google Scholar
Essali, A, Ali, G (2012). Antipsychotic drug treatment for elderly people with late-onset schizophrenia. Cochrane Database Syst Rev, (2), CD004162.Google ScholarPubMed
Evans, DL, Charney, DS, Lewis, L, et al. (2005). Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry, 58, 175–189.Google Scholar
Finkelstein, J, Friedman, C, Hripcsak, G, Cabrera, M (2016). Pharmacogenetic polymorphism as an independent risk factor for frequent hospitalizations in older adults with polypharmacy: a pilot study. Pharmgenomics Pers Med, 14, 107–116.Google Scholar
Firoz, S, Carlson, G (2004). Characteristics and treatment outcome of older methadone-maintenance patients. Am J Geriatr Psychiatry, 12, 539–541.Google Scholar
Flockhart, D (undated). Flockhart Table P450 Drug Interaction Table. Available at: http://medicine.iupui.edu/clinpharm/ddis/main-table (last accessed 25.3.17).Google Scholar
Glassman, AH, O’Connor, CM, Califf, RM, et al. (2002). Sertraline treatment of major depression in patients with acute MI or unstable angina. Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. JAMA, 288, 701–709.CrossRefGoogle ScholarPubMed
Goodwin, GM, Haddad, PM, Ferrier, IN, et al. (2016). Evidence-based guidelines for treating bipolar disorder: revised third edition recommendations from the British Association for Psychopharmacology. J Psychopharmacol, 30, 495–553.CrossRefGoogle ScholarPubMed
Gray, SL, Dublin, S, Yu, O, et al. (2016). Benzodiazepine use and risk of incident dementia or cognitive decline: prospective population based study. BMJ, 352, i90.Google Scholar
Gray, SL, Hart, LA, Perera, S, et al. (2018). Meta-analysis of interventions to reduce adverse drug reactions in older adults. J Am Geriatr Soc, 66, 282–288.Google Scholar
Greenblatt, DJ, Harmatz, JS, Shapiro, L, et al. (1991). Sensitivity to triazolam in the elderly. N Engl J Med, 324, 1691–1698.Google Scholar
Gum, AM, King-Kallimanis, B, Kohn, R (2009). Prevalence of mood, anxiety, and substance-abuse disorders for older Americans in the National Comorbidity Survey-Replication. Am J Geriatr Psychiatry, 17, 769–781.Google Scholar
Heun, R, Ahokas, A, Boyer, P, et al. (2013). The efficacy of agomelatine in elderly patients with recurrent major depressive disorder: a placebo-controlled study. J Clin Psychiatry, 74, 587–594.Google Scholar
Hewett, K, Gee, MD, Krishen, A, et al. (2010). Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. J Psychopharmacol, 24, 1209–1216.Google Scholar
Jeste, DV, Barak, Y, Madhusoodanan, S, Grossman, F, Gharabawi, G (2003). International multisite double-blind trial of the atypical antipsychotics risperidone and olanzapine in 175 elderly patients with chronic schizophrenia. Am J Geriatr Psychiatry, 11, 638–647.CrossRefGoogle ScholarPubMed
Joint Formulary Committee (2017). British National Formulary, No. 73. London: BMJ Group and Pharmaceutical Press, p. 296 and p. 304.Google Scholar
Katila, H, Mezhebovsky, I, Mulroy, A, et al. (2013). Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry, 21, 769–784.Google Scholar
Katona, C, Bercoff, E, Chiu, E, et al. (1999). Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: a double-blind randomised trial. J Affect Disord, 55, 203–213.Google Scholar
Katona, C, Hansen, T, Olsen, CK (2012). A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of LU AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol, 27, 215–223.Google Scholar
Katz, IR, Reynolds, CF, III Alexopoulos, GS, Hackett, D (2002). Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J Am Geriatr Soc, 50, 18–25.Google Scholar
Kerr, KP, Mate, KE, Magin, PJ, et al. (2014). The prevalence of co-prescription of clinically relevant CYP enzyme inhibitor and substrate drugs in community-dwelling elderly Australians. J Clin Pharm Ther, 39, 383–389.Google Scholar
Kessler, D, MacNeill, SJ, Tallon, D, et al. (2018). Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised controlled trial (MIR). BMJ, 363, k4218.CrossRefGoogle ScholarPubMed
Kinsella, K, He, W (2009). An Aging World. Washington, DC: National Institute on Aging and US Census Bureau.Google Scholar
Kirchheiner, J, Seeringer, A (2007). Clinical implications of pharmacogenetics of cytochrome P450 drug metabolizing enzymes. Biochim Biophys Acta, 1770, 489–494.Google Scholar
Klotz, U (2009). Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev, 41, 67–76.Google Scholar
Kok, RM, Vink, D, Heeren, TJ, Nolen, WA (2007). Lithium augmentation compared with phenelzine in treatment-resistant depression in the elderly: an open, randomized, controlled trial. J Clin Psychiatry, 68, 1177–1185.Google Scholar
Kok, RM, Heeren, TJ, Nolen, WA (2011). Continuing treatment of depression in the elderly: a systematic review and meta-analysis of double-blinded randomized controlled trials with antidepressants. Am J Geriatr Psychiatry, 19, 249–255.Google Scholar
Kok, RM, Nolen, WA, Heeren, TJ (2012). Efficacy of treatment in older depressed patients: a systematic review and meta-analysis of double-blind randomized controlled trials with antidepressants J Affect Disord, 141, 103–115.CrossRefGoogle ScholarPubMed
Lampon, N, Tutor, JC (2012). Apparent clearance of valproic acid in elderly epileptic patients: estimation of the confounding effect of albumin concentration. Ups J Med Sci, 117, 41–46.CrossRefGoogle ScholarPubMed
Lavretsky, H, Reinlieb, M, St Cyr, N, et al. (2015). Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry, 172, 561–569.CrossRefGoogle ScholarPubMed
Lenze, EJ, Mulsant, BH, Shear, MK, et al. (2005). Efficacy and tolerability of citalopram in the treatment of late-life anxiety disorders: results from an 8-week randomized, placebo-controlled trial. Am J Psychiatry, 162, 146–150.CrossRefGoogle ScholarPubMed
Lenze, EJ, Rollman, BL, Shear, MK, et al. (2009). Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial. JAMA, 301, 295–303.Google Scholar
Lenze, EJ, Mulsant, BH, Blumberger, DM, et al. (2015). Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial. Lancet, 386(10011), 2404–2412.CrossRefGoogle ScholarPubMed
Lieberman, JA, III (2004). Managing anticholinergic side effects. Prim Care Companion J Clin Psychiatry, 6(Suppl 2), 20–23.Google Scholar
Lin, FY, Chen, PC, Liao, CH, Hsieh, YW, Sung, FC (2014). Retrospective population cohort study on hip fracture risk associated with zolpidem medication. Sleep, 37, 673–679.Google Scholar
Lindeman, R, Tobin, J, Shock, N (1985). Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc, 33, 278–285.CrossRefGoogle ScholarPubMed
Lipscombe, LL, Lévesque, L, Gruneir, A, et al. (2009). Antipsychotic drugs and hyperglycemia in older patients with diabetes. Arch Intern Med, 169, 1282–1289.Google Scholar
MacQueen, GM, Frey, BN, Ismail, Z, et al.; CANMAT Depression Work Group (2016). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 Clinical Guidelines for the Management of Adults with Major Depressive Disorder: Section 6. Special Populations: Youth, Women, and the Elderly. Can J Psychiatry, 61, 588–603.Google Scholar
Madhusoodanan, S, Zaveri, D (2010). Paliperidone use in the elderly. Curr Drug Saf, 5, 149–152.Google Scholar
Maneeton, N, Maneeton, B, Woottiluk, P, et al. (2016). Quetiapine monotherapy in acute treatment of generalized anxiety disorder: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther, 10, 259–276.CrossRefGoogle ScholarPubMed
Maust, DT, Kim, HM, Seyfried, LS (2015). Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry, 72, 438–445.Google Scholar
Mezuk, B, Morden, NE, Ganoczy, D, Post, EP, Kilbourne, AM (2010). Anticonvulsant use, bipolar disorder, and risk of fracture among older adults in the Veterans Health Administration. Am J Geriatr Psychiatry, 18, 245–255.Google Scholar
Michelson, D, Snyder, E, Paradis, E, et al. (2014). Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol, 13, 461–471.Google Scholar
Mizuno, Y, Suzuki, T, Nakagawa, A, et al. (2014). Pharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis. Schizophr Bull, 40, 1385–1403.Google Scholar
Møller, M, Jakobsen, S, Gjedde, A (2007). Parametric and regional maps of free serotonin 5HT1A receptor sites in human brain as function of age in healthy humans. Neuropsychopharmacology, 32, 1707–1714.Google Scholar
Montgomery, S, Chatamra, K, Pauer, L, Whalen, E, Baldinetti, F (2008). Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder. Br J Psychiatry, 193, 389–394.CrossRefGoogle ScholarPubMed
Morgan, DG, May, PC, Finch, CE (1987). Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am Geriatr Soc, 35, 334–345.Google Scholar
Musselman, DL, Tomer, A, Manatunga, AK, et al. (1996). Exaggerated platelet reactivity in major depression. Am J Psychiatry, 153, 1313–1317.Google Scholar
Nurmi-Lüthje, I, Kaukonen, JP, Lüthje, P, et al. (2006). Use of benzodiazepines and benzodiazepine-related drugs among 223 patients with an acute hip fracture in Finland: comparison of benzodiazepine findings in medical records and laboratory assays. Drugs Aging, 23, 27–37.Google Scholar
O’Connor, DW, Sierakowski, C, Chin, LF, Singh, D (2010). The safety and tolerability of clozapine in aged patients: a retrospective clinical file review. World J Biol Psychiatry, 11, 788–791.Google Scholar
Ormhøj, SS, Pottegård, A, Gasse, C, Rasmussen, L (2018). Use of attention-deficit/hyperactivity disorder medication among older adults in Denmark. Br J Clin Pharmacol, 84, 1505–1513. doi:10.1111/bcp.13569.Google Scholar
Ortega, V, Tabet, N, Nilforooshan, R, Howard, R (2017). Efficacy of antidepressants for depression in Alzheimer’s disease: systematic review and meta-analysis. J Alzheimers Dis, 58, 725–733.Google Scholar
Pridan, S, Swartz, M, Baruch, Y, et al. (2015). Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia. Int Psychogeriatr, 27, 131–134.CrossRefGoogle ScholarPubMed
Prince, M, Bryce, R, Albanese, E (2013). The global prevalence of dementia: a systematic review and meta-analysis. Alzheimers Dement (N Y), 9, 63–75.Google Scholar
Punyawudho, B, Ramsay, ER, Brundage, RC, et al. (2012). Population pharmacokinetics of carbamazepine in elderly patients. Ther Drug Monit, 34, 176–181.Google Scholar
Qirjazi, E, McArthur, E, Nash, DM, et al. (2016). Risk of ventricular arrhythmia with citalopram and escitalopram: a population-based study. PLoS One, 11(8), e0160768.Google Scholar
Raskin, J, Wiltse, CG, Siegal, A, et al. (2007). Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial. Am J Psychiatry, 164, 900–909.Google Scholar
Regier, DA, Boyd, JH, Burke, JD Jr, et al. (1988). One-month prevalence of mental disorders in the United States. Based on five epidemiologic catchment area sites. Arch Gen Psychiatry, 45, 977–986.Google Scholar
Rehman, HU, Masson, EA (2001). Neuroendocrinology of ageing. Age Ageing, 30, 279–287.CrossRefGoogle ScholarPubMed
Rej, S, Herrmann, N, Shulman, K, et al. (2016). Farewell mood stabilizers? Current psychotropic medication prescribing patterns in late-life bipolar disorder. Am J Geriatr Psychiatry, 24(3 Suppl), S86–S87.Google Scholar
Rinne, JO (1987). Muscarinic and dopaminergic receptors in ageing human brain. Brain Res, 404, 161–168.Google Scholar
Rosenberg, PB, Drye, LT, Martin, BK, et al.; DIADS-2 Research Group (2010). Sertraline for the treatment of depression in Alzheimer disease. Am J Geriatr Psychiatry, 18, 136–145.Google Scholar
Roth, M, Mountjoy, CQ, Amrein, R (1996). Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry, 168, 149–157.Google Scholar
Rudolph, JL, Salow, MJ, Angelini, MC, McGlinchey, RE (2008). The anticholinergic risk scale and anticholinergic adverse effects in older persons. Arch Intern Med, 168, 508–513.Google Scholar
Sabesan, P, Lankappa, S, Khalifa, N, et al. (2015). Transcranial magnetic stimulation for geriatric depression: promises and pitfalls. World J Psychiatry, 5(2), 170–181.Google Scholar
Sajatovic, M, Coconcea, N, Ignacio, RV, et al. (2008). Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial. J Clin Psychiatry, 69, 41–46.Google Scholar
Sajatovic, M, Strejilevich, SA, Gildengers, AG, et al. (2015). A report on older-age bipolar disorder from the International Society for Bipolar Disorders Task Force. Bipolar Disord, 17, 689–704.Google Scholar
Sajatovic, M, Forester, BP, Tsai, J, et al. (2016). Efficacy of lurasidone in adults aged 55 years and older with bipolar depression: post hoc analysis of 2 double-blind, placebo-controlled studies. J Clin Psychiatry, 77(10), e1324–e1331.Google Scholar
Schatzberg, AF, Kremer, C, Rodrigues, HE, Murphy, GM Jr (2002). Mirtazapine vs. Paroxetine Study Group. Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. Am J Geriatr Psychiatry, 10, 541–550.Google Scholar
Schneider, LS, Nelson, JC, Clary, CM, et al.; Sertraline Elderly Depression Study Group (2003). An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry, 160, 1277–1285.Google Scholar
Shroeck, J, Ford, J, Conway, EL, et al. (2016). Review of safety and efficacy of sleep medicines in older adults. Clin Ther, 38, 2340–2372.Google Scholar
Singh, S, Bajorek, B (2015). Pharmacotherapy in the ageing patient: the impact of age per se (a review). Ageing Res Rev, 24(Pt B), 99–110.Google Scholar
Sommer, BR, Fenn, HH (2010). Review of topiramate for the treatment of epilepsy in elderly patients. Clin Interv Aging, 5, 89–99.Google Scholar
Stage, KB, Kragh-Sørensen, PB; Danish University Antidepressant Group (2002). Age-related adverse drug reactions to clomipramine. Acta Psychiatr Scand, 105, 55–59.Google Scholar
Stranks, EK, Crowe, SF (2014). The acute cognitive effects of zopiclone, zolpidem, zaleplon, and eszopiclone: a systematic review and meta-analysis. J Clin Exp Neuropsychol, 36, 691–700.Google Scholar
Tedeschini, E, Levkovitz, Y, Iovieno, N, et al. (2011). Efficacy of antidepressants for late-life depression: a meta-analysis and meta-regression of placebo-controlled randomized trials. J Clin Psychiatry, 72, 1660–1668.Google Scholar
Terzano, MG, Rossi, M, Palomba, V, Smerieri, A, Parrino, L (2003). New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon. Drug Saf, 26, 261–282.CrossRefGoogle ScholarPubMed
Thomas, RE (1998). Benzodiazepine use and motor vehicle accidents. Systematic review of reported association. Can Fam Physician, 44, 799–808.Google Scholar
Thorlund, K, Druyts, E, Wu, P, et al. (2015). Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc, 63, 1002–1009.Google Scholar
Tzimos, A, Samokhvalov, V, Kramer, M, et al. (2008). Safety and tolerability of oral paliperidone extended-release tablets in elderly patients with schizophrenia: a double-blind, placebo-controlled study with six-month open-label extension. Am J Geriatr Psychiatry, 16, 31–43.CrossRefGoogle ScholarPubMed
Vestergaard, P, Rejnmark, L, Mosekilde, L (2006). Fracture risk associated with the use of morphine and opiates. J Intern Med, 260, 76–87.Google Scholar
Waade, RB, Hermann, M, Moe, HL, Molden, E (2014). Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups. Eur J Clin Pharmacol, 70, 933–940.Google Scholar
Wegner, I, Wilhelm, AJ, Sander, JW, Lindhout, D (2013). The impact of age on lamotrigine and oxcarbazepine kinetics: a historical cohort study. Epilepsy Behav, 29, 217–221.Google Scholar
Weihs, KL, Settle, EC Jr, Batey, SR, et al. (2000). Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. J Clin Psychiatry, 61, 196–202.Google Scholar
Wildiers, H, Highley, MS, de Bruijn, EA, van Oosterom, AT (2003). Pharmacology of anticancer drugs in the elderly population. Clin Pharmacokinet, 42, 1213–1242.Google Scholar
Young, RC, Mulsant, BH, Sajatovic, M, et al.; GERI-BD Study Group (2017). GERI-BD: a randomized double-blind controlled trial of lithium and divalproex in the treatment of mania in older patients with bipolar disorder. Am J Psychiatry, 174, 1086–1093.CrossRefGoogle ScholarPubMed
Zolezzi, M (2016). Medication management during electroconvulsant therapy. Neuropsychiatr Dis Treat, 12, 931–939.Google Scholar

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×